<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Requests for Reconsideration at the Division Level Under the Generic Drug User Fee Amendments; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Requests for Reconsideration at the Division Level Under the Generic Drug User Fee Amendments; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2024-10-17 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Requests for Reconsideration at the Division Level Under GDUFA." This guidance provides recommendations on the procedures for applicants of abbreviated new drug applications (ANDAs) that wish to pursue a request for reconsideration within the review discipline at the division level or original signatory authority. This guidance reflects the most recent reauthorization of the...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-23967</p>
    <p><strong>Publication Date:</strong> 2024-10-17</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/10/17/2024-23967/requests-for-reconsideration-at-the-division-level-under-the-generic-drug-user-fee-amendments">https://www.federalregister.gov/documents/2024/10/17/2024-23967/requests-for-reconsideration-at-the-division-level-under-the-generic-drug-user-fee-amendments</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-23967</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
